BRCA1 and cancer: Comparison with a validated NGS-based assay on 209 FFPE clinical specimens from cancer patients (5 tBRCA1/2* GISMC −; 71 tBRCA1/2WT GISMC −; 66 tBRCA1/2* GISMC +; 61 tBRCA1/2WT GISMC +) indicated 99.9% PPA (95% lower limit confidence of 99.7%), 100% NPA for BRCA1/2 SNVs/indels and 100% OPA for tBRCA LR.